Skip to main content
Medical information Clinical review pending

Genetic Testing

NIPT Advanced for 23 Chromosomes

A non-invasive blood test during pregnancy to screen for common chromosomal abnormalities in the fetus, such as Down syndrome. Provides early risk assessment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Maternal blood sample (typically 10mL).
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for this blood test.
Test priceKSh 26,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NIPT Advanced for 23 Chromosomes test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Screening for common chromosomal abnormalities during pregnancy
  • ✓Women aged 35 years or older
  • ✓Family history of chromosomal abnormalities
  • ✓Abnormal ultrasound findings
  • ✓Previous pregnancy affected by chromosomal abnormalities
  • ✓Informed decision-making during pregnancy
02

In plain language

What this test helps you understand

Screens for common fetal chromosomal abnormalities using cell-free fetal DNA from maternal blood. Provides risk assessment for conditions like Down syndrome, Edwards syndrome, and Patau syndrome.
The NIPT Advanced for 23 Chromosomes is a non-invasive prenatal test (NIPT) that screens for common chromosomal abnormalities in a developing fetus. This test analyzes cell-free fetal DNA found in the pregnant woman's blood. It is a safe option for expectant parents seeking early information about their baby's genetic health.

This test screens for conditions including Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome), as well as other sex chromosome abnormalities.

Consider discussing this test with your doctor if you are 35 or older, have a family history of genetic disorders, have had abnormal ultrasound findings, or have had previous pregnancies affected by chromosomal abnormalities.

Benefits include being non-invasive, having high accuracy for screening, allowing for early risk assessment, and providing peace of mind. Results typically indicate a low or high risk for specific conditions. A high-risk result may lead to recommendations for further diagnostic testing. Confirm with the laboratory before booking.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this blood test.
SampleMaternal blood sample (typically 10mL).
MethodologyAnalysis of cell-free fetal DNA in maternal plasma using Next Generation Sequencing (NGS).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This is a screening test, not a diagnostic test. A high-risk result requires confirmation with diagnostic testing like amniocentesis or CVS. The test may not detect all chromosomal abnormalities or other genetic conditions. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

NIPT stands for Non-Invasive Prenatal Testing. It's a blood test taken during pregnancy that screens for certain chromosomal abnormalities in the fetus.
No, this test only requires a maternal blood sample, making it non-invasive and safe for both mother and baby.
The test screens for common chromosomal conditions like Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
A high-risk result indicates an increased chance of a chromosomal abnormality. Your doctor will discuss the result with you and may recommend further diagnostic testing, such as amniocentesis or CVS, to confirm the findings.
NIPT has high accuracy for screening the conditions it tests for, but it is still a screening test. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp